[123 I]-EP/CIT SPECT imaging for distinguishing drug-induced Parkinsonism from Parkinson's disease

Movement Disorders

Volumn 21, Issue 4, 2006, Pages 510-514

  Loberboym, Mordechai ^a   Traves, Therese A ^a   Melamed, Eldad ^b   Lampl, Yair ^a   Hellman, Mark ^b   Djaldetti, Ruth ^b,c  

^a WOLFSON MEDICAL CENTER   (Israel)

^b RABIN MEDICAL CENTER   (Israel)

^c TEL AVIV UNIVERSITY   (Israel)

Author keywords

123 I FP CIT SPECT; Drug induced Parkinsonism; Parkinson's disease; Presynaptic degeneration

Indexed keywords

IOFLUPANE; N OMEGA FLUOROPROPYL 2 BETA CARBOXYMETHOXY 3 BETA [4 IODOPHENYL]TROPANE I 123; NEUROLEPTIC AGENT; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; 2 CARBOMETHOXY 8 (3 FLUOROPROPYL) 3 (4 IODOPHENYL)TROPANE; 2-CARBOMETHOXY-8-(3-FLUOROPROPYL)-3-(4-IODOPHENYL)TROPANE; DIAGNOSTIC AGENT; RADIOACTIVE IODINE; TROPANE DERIVATIVE;

ADULT; AGED; ARTICLE; BRADYKINESIA; BRAIN SCINTISCANNING; CAUDATE NUCLEUS; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; CORPUS STRIATUM; DISEASE EXACERBATION; DOPAMINE RECEPTOR BLOCKING; DRUG BINDING; DRUG INDUCED DISEASE; FEMALE; GAIT DISORDER; HUMAN; MALE; MENTAL DISEASE; NEUROIMAGING; NEUROLOGIC EXAMINATION; PARKINSON DISEASE; PARKINSONISM; PRESYNAPTIC INHIBITION; PRIORITY JOURNAL; PUTAMEN; RATING SCALE; RIGIDITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STRIATONIGRAL DEGENERATION; TREMOR; CASE CONTROL STUDY; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; HOSPITALIZATION; IMAGE PROCESSING; METHODOLOGY; MIDDLE AGED; NONPARAMETRIC TEST; SCINTISCANNING;

AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; FEMALE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; PARKINSON DISEASE; PARKINSONIAN DISORDERS; SEVERITY OF ILLNESS INDEX; STATISTICS, NONPARAMETRIC; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TROPANES;

EID: 33646231500     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.20748     Document Type: Article

References (25)

1. Marti-Massó JF, Caffera N, Urtasun M. Drug-induced parkinsonism: a growing list [letter]. Mov Disord 1993;8:125.
2. Chakos MH, Mayerhoff DI, Loebel AD, Alvir JM, Lieberman JA. Incidence and correlates of acute extrapyramidal symptoms in first episode of schizophrenia. Psychopharmacol Bull 1992;28:81-86.
3. McCreadie RG. The Nithsdale schizophrenia surveys. An overview. Soc Psychiatry Psychiatr Epidemiol 1992;27:40-45.
4. Ayd FJ. A survey of drug-induced extrapyramidal reactions. JAMA 1961;175:1054-1060.
5. Stephen PJ, Williamson J. Drug-induced parkinsonism in the elderly. Lancet 1984;2:1082-1083.
6. Miller LG, Jankovic J. Metoclopramide-induced movement disorders. Arch Intern Med 1989; 149:2486-2492.
7. Hansen TE, Brown WL, Weigel RM, Casey DE. Underrecognition of tardive dyskinesia and drug-induced parkinsonism by psychiatric residents. Gen Hosp Psychiatry 1992;14:340-344.
8. Hausner RS. Neuroleptic-induced parkinsonism and Parkinson's disease: differential diagnosis and treatment. J Clin Psychiatry 1983;44:13-16.
9. Hassin-Baer S, Sirota P, Korczyn AD, et a]. Clinical characteristics of neuroleptic-induced parkinsonism. J Neural Transm 2001;108: 1299-1308.
10. Tolosa E, Coelho M, Gallardo M. DAT imaging in drug-induced and psychogenic parkinsonism. Mov Disord 2003;18(Suppl. 7): S28-S33.
11. 123I]FP-CIT SPECT in differentiating patients with presynaptic parkinsonism from those with other forms of parkinsonism. Eur J Nucl Med 2001;28:266-272.
12. 123]I FP-CIT SPECT. Schizophr Res 2001;47:59-67.
13. Dao-Castellana MH, Paillere-Martinot ML, Hantraye P, et al. Presynaptic dopaminergic function in the striatum of schizophrenic patients. Schizophr Res 1997;23:167-174.
14. Reith J, Benkelfat C, Sherwin A, et al. Elevated dopa decarboxylase activity in living brain of patients with psychosis. Proc Natl Acad Sci U S A 1994;91:11651-11654.
15. Hietala J, Syvalahti E, Vuorio K, et al. Presynaptic dopamine function in striatum of neuroleptic-naive schizophrenic patients. Lancet 1995;346:1130-1131.
16. Meyer-Lindenberg A, Miletich RS, Kohn PD, et al. Reduced prefrontal activity predicts exaggerated striatal dopaminergic function in schizophrenia. Nat Neurosci 2002;5:267-271.
17. McGowan S, Lawrence AD, Sales T, Quested D, Grasby P. Presynaptic dopaminergic dysfunction in schizophrenia. A positron emission tomographic [18F]fluorodopa study. Arch Gen Psychiatry 2004;61:134-142.
18. Laakso A, Bergman J, Haaparanta M, et al. Decreased striatal dopamine transporter binding in vivo in chronic schizophrenia. Schizophr Res 2001;52:115-120.
19. 18 F-dopa PET study. Neurology 1993;43:552-556.
20. Korczyn AD, Goldberg GJ. Extrapyramidal effects of neuroleptics. J Neurol Neurosurg Psychiatry 1976;39:866-869.
21. Klawans HL, Bergen D, Bruyn GW. Prolonged drug-induced Parkinsonism. Confin Neurol 1973;35:368-377.
22. Melamed E, Achiron A, Shapira A, Davidovicz S. Persistent and progressive parkinsonism after discontinuation of chronic neuroleptic therapy: an additional tardive syndrome? Clin Neuropharmacol 1991;14:273-278.
23. Hardie RJ, Lees AJ. Neuroleptic-induced Parkinson's syndrome: clinical features and results of treatment with levodopa. J Neurol Neurosurg Psychiatry 1988;51:850-854.
24. Goetz CG. Drug-induced parkinsonism and idiopathic Parkinson's disease. Arch Neurol 1983;40:325-326.
25. Rajput AH, Rozdilsky B, Hornykiewicz O, Shannak K, Lee T, Seeman P. Reversible drug-induced parkinsonism. Clinicopathologic study of two cases. Arch Neurol 1982;39:644-646.